Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

KALV – KalVista Pharmaceuticals Inc

KalVista Pharmaceuticals, Inc.
KALV
$13.21
Name : KalVista Pharmaceuticals, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $659,888,384.00
EPSttm : -3.69
finviz dynamic chart for KALV
KalVista Pharmaceuticals, Inc.
$13.21
3.08%
$0.42

Float Short %

23.97

Margin Of Safety %

Put/Call OI Ratio

0.28

EPS Next Q Diff

0.09

EPS Last/This Y

0.38

EPS This/Next Y

1.14

Price

13.21

Target Price

31.67

Analyst Recom

1

Performance Q

-2.87

Relative Volume

0.74

Beta

0.04

Ticker: KALV




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-04KALV12.030.120.7915476
2025-07-07KALV15.060.120.5015568
2025-07-08KALV14.950.210.1117639
2025-07-09KALV15.960.210.0317868
2025-07-10KALV15.50.200.5118170
2025-07-11KALV14.50.220.2518839
2025-07-14KALV15.230.231.0818903
2025-07-15KALV15.170.260.0319623
2025-07-16KALV15.790.260.0919661
2025-07-17KALV16.010.260.1019560
2025-07-18KALV15.380.260.1919519
2025-07-21KALV15.530.280.0212732
2025-07-22KALV15.810.280.1812738
2025-07-23KALV15.560.280.0712775
2025-07-24KALV15.60.280.1412742
2025-07-25KALV14.580.280.0512738
2025-07-28KALV13.570.280.7912813
2025-07-29KALV13.750.280.2212849
2025-07-30KALV13.850.280.0012896
2025-07-31KALV13.610.280.1113081
2025-08-01KALV13.220.280.4113045
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-04KALV11.9822.3- -3.56
2025-07-07KALV15.0522.3- -3.56
2025-07-08KALV14.9522.3- -3.56
2025-07-09KALV15.9922.3- -3.56
2025-07-10KALV15.5122.3- -3.56
2025-07-11KALV14.5222.3- -3.56
2025-07-14KALV15.2222.3- -3.56
2025-07-15KALV15.1722.3- -3.56
2025-07-16KALV15.7922.3- -3.56
2025-07-17KALV16.0122.3- -3.56
2025-07-18KALV15.3922.3- -3.56
2025-07-21KALV15.5722.3- -3.56
2025-07-22KALV15.8222.3- -3.56
2025-07-23KALV15.5622.3- -3.56
2025-07-24KALV15.6022.3- -3.56
2025-07-25KALV14.5822.3- -3.56
2025-07-28KALV13.6422.3- -3.56
2025-07-29KALV13.7522.3- -3.56
2025-07-30KALV13.8422.3- -3.56
2025-07-31KALV13.6322.3- -3.56
2025-08-01KALV13.21-10.2- -3.31
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-04KALV2.78-6.3516.25
2025-07-07KALV2.78-6.3716.25
2025-07-08KALV2.78-6.3716.25
2025-07-09KALV2.78-6.3716.25
2025-07-10KALV2.78-6.3716.25
2025-07-11KALV2.19-6.3722.08
2025-07-14KALV2.18-0.7022.02
2025-07-15KALV2.16-0.7022.02
2025-07-16KALV2.16-0.7022.02
2025-07-17KALV2.16-0.7022.02
2025-07-18KALV2.16-0.7022.02
2025-07-21KALV2.16-6.0422.02
2025-07-22KALV2.16-6.0422.02
2025-07-23KALV2.16-6.0422.02
2025-07-24KALV2.16-6.0422.02
2025-07-25KALV2.16-6.0423.97
2025-07-28KALV2.16-6.1623.97
2025-07-29KALV2.16-6.1623.97
2025-07-30KALV2.16-6.1623.97
2025-07-31KALV2.16-6.1623.97
2025-08-01KALV2.16-6.1623.97
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-0.99

Avg. EPS Est. Current Quarter

-0.83

Avg. EPS Est. Next Quarter

-0.9

Insider Transactions

2.16

Institutional Transactions

-6.16

Beta

0.04

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

4

Fair Value

Quality Score

11

Growth Score

23

Sentiment Score

17

Actual DrawDown %

70.6

Max Drawdown 5-Year %

-90.1

Target Price

31.67

P/E

Forward P/E

PEG

P/S

P/B

6.89

P/Free Cash Flow

EPS

-3.75

Average EPS Est. Cur. Y​

-3.31

EPS Next Y. (Est.)

-2.17

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.74

Return on Equity vs Sector %

-216

Return on Equity vs Industry %

-197.4

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.33

EBIT Estimation

KalVista Pharmaceuticals, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 270
KalVista Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is EKTERLY, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. KalVista Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.
stock quote shares KALV – KalVista Pharmaceuticals Inc Stock Price stock today
news today KALV – KalVista Pharmaceuticals Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch KALV – KalVista Pharmaceuticals Inc yahoo finance google finance
stock history KALV – KalVista Pharmaceuticals Inc invest stock market
stock prices KALV premarket after hours
ticker KALV fair value insiders trading